NYSE:EW

Edwards Lifesciences (EW) Stock Price, News & Analysis

$87.04
-1.57 (-1.77%)
(As of 10:03 AM ET)
Today's Range
$86.81
$88.00
50-Day Range
$84.87
$95.56
52-Week Range
$60.57
$96.12
Volume
275,661 shs
Average Volume
3.78 million shs
Market Capitalization
$52.39 billion
P/E Ratio
37.84
Dividend Yield
N/A
Price Target
$91.73

Edwards Lifesciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.53 Rating Score
Upside/​Downside
3.5% Upside
$91.73 Price Target
Short Interest
Healthy
1.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.44mentions of Edwards Lifesciences in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$17.17 M Sold Last Quarter
Proj. Earnings Growth
11.96%
From $2.76 to $3.09 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.37 out of 5 stars

Medical Sector

112th out of 907 stocks

Surgical Appliances & Supplies Industry

6th out of 18 stocks

EW stock logo

About Edwards Lifesciences Stock (NYSE:EW)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

EW Stock Price History

EW Stock News Headlines

The 5 Stocks Most Sold By Insiders This Year (EW)
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Edwards Lifesciences Corporation (EW)
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
What Analysts Are Saying About Edwards Lifesciences Stock
Evercore ISI Remains a Hold on Edwards Lifesciences (EW)
See More Headlines
Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/06/2024
Today
4/25/2024
Next Earnings (Confirmed)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
CUSIP
28176E10
Employees
19,800
Year Founded
1958

Price Target and Rating

Average Stock Price Target
$91.73
High Stock Price Target
$107.00
Low Stock Price Target
$57.00
Potential Upside/Downside
+3.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
17 Analysts

Profitability

Net Income
$1.40 billion
Pretax Margin
26.61%

Debt

Sales & Book Value

Annual Sales
$6.00 billion
Cash Flow
$2.82 per share
Book Value
$11.08 per share

Miscellaneous

Free Float
594,283,000
Market Cap
$53.34 billion
Optionable
Optionable
Beta
1.05

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

  • Edwards Lifesciences has shown consistent growth in its stock price, reaching a 52-week high of $95.27.
  • The company's focus on structural heart disease and critical care monitoring products positions it well in the healthcare sector, which has long-term growth potential.
  • Recent institutional investments in the company indicate confidence from major players in the market.
  • Edwards Lifesciences' innovative transcatheter heart valve replacement products under the SAPIEN family offer minimally invasive solutions for aortic valve replacement.
  • The company's strong financial health, with a current ratio of 3.38 and a quick ratio of 2.40, provides stability and liquidity for investors.

Cons

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

  • The company's price-to-earnings ratio of 40.13 and price-to-earnings-growth ratio of 4.61 may indicate a relatively high valuation compared to industry peers.
  • While the company has shown growth, there may be increased competition in the healthcare sector, leading to potential market share challenges.
  • Fluctuations in healthcare regulations and reimbursement policies could impact Edwards Lifesciences' revenue and profitability.
  • Market volatility and macroeconomic factors could affect the company's stock performance, making it susceptible to external economic conditions.
  • Investors should consider the company's debt-to-equity ratio of 0.09 as part of their risk assessment when investing in Edwards Lifesciences.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com.

EW Stock Analysis - Frequently Asked Questions

Should I buy or sell Edwards Lifesciences stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EW shares.
View EW analyst ratings
or view top-rated stocks.

What is Edwards Lifesciences' stock price target for 2024?

17 Wall Street research analysts have issued 1-year price objectives for Edwards Lifesciences' stock. Their EW share price targets range from $57.00 to $107.00. On average, they anticipate the company's stock price to reach $91.73 in the next year. This suggests a possible upside of 3.5% from the stock's current price.
View analysts price targets for EW
or view top-rated stocks among Wall Street analysts.

How have EW shares performed in 2024?

Edwards Lifesciences' stock was trading at $76.25 at the beginning of the year. Since then, EW shares have increased by 16.2% and is now trading at $88.62.
View the best growth stocks for 2024 here
.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 10,450,000 shares, an increase of 23.8% from the February 29th total of 8,440,000 shares. Based on an average daily trading volume, of 3,940,000 shares, the days-to-cover ratio is presently 2.7 days. Currently, 1.8% of the company's stock are sold short.
View Edwards Lifesciences' Short Interest
.

When is Edwards Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our EW earnings forecast
.

How can I listen to Edwards Lifesciences' earnings call?

Edwards Lifesciences will be holding an earnings conference call on Thursday, April 25th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) issued its quarterly earnings data on Tuesday, February, 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting the consensus estimate of $0.64. The medical research company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 23.56% and a net margin of 23.35%. The business's revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.64 earnings per share.
Read the conference call transcript
.

When did Edwards Lifesciences' stock split?

Shares of Edwards Lifesciences split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were payable to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its first quarter 2024 earnings guidance on Tuesday, February, 6th. The company provided EPS guidance of 0.620-0.660 for the period, compared to the consensus EPS estimate of 0.660. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Raymond James & Associates (0.29%), Sumitomo Mitsui Trust Holdings Inc. (0.27%), Raymond James Financial Services Advisors Inc. (0.19%), Assenagon Asset Management S.A. (0.15%), Factory Mutual Insurance Co. (0.08%) and Allspring Global Investments Holdings LLC (0.05%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daniel J Lippis, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends
.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Edwards Lifesciences have any subsidiaries?
The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.
Read More
This page (NYSE:EW) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners